Dissemin is shutting down on January 1st, 2025

Published in

Elsevier, Neurobiology of Aging, 7(33), p. 1486.e9-1486.e15

DOI: 10.1016/j.neurobiolaging.2011.02.008

Links

Tools

Export citation

Search in Google Scholar

Using CSF biomarkers to replicate genetic associations in Alzheimer's disease

Journal article published in 2011 by S. Vethanayaki Arumughababu, B. V. Sumana, Marleen de Bruijne, Leyla deToledo-Morrell, Shen-Ming, Antonio Martinez Torteya, Cesare Moises Ovando Vazquez, Hauke Schramm, Markus Schuerch, Timothy Schultz, Eben Schwartz, Pamela Schwartz, John Schwarz, Adam Schwarz, Tom Schweizer and other authors.
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Defining cases and controls on the basis of biomarkers rather than clinical diagnosis may reduce sample sizes required for genetic studies. The aim of this study was to assess whether characterizing case/control status on the basis of cerebrospinal fluid (CSF) profile would increase power to replicate known genetic associations for Alzheimer's disease (AD). Independent of clinical diagnosis, Alzheimer's Disease Neuroimaging Initiative (ADNI) subjects with 2 CSF biomarkers for AD (Abeta1-42 23 pg/mL, "CSF-positive") were compared with those without CSF evidence for AD (Abeta1-42 > 192 pg/mL and 181-phosphorylated tau